NeurologyLive® Brain Games : 12 mars 2023

Published Date: 16 Mar 2023

Test your neurology knowledge with NeurologyLive®'s weekly quiz featuring questions on a variety of clinical and neurological history topics. This week's theme is movement.

Read Full News

Latest News

Norwegian Registry Study Links Maternal Diabetes to Doubled Risk of Multiple Sclerosis in Offspring Marco Meglio

A recent study linked maternal diabetes to a doubled risk of multiple sclerosis in offspring, highlighting prenatal factors in MS susceptibility.

Priority Review Granted for Weekly Subcutaneous Lecanemab Dosing in Early Alzheimer Disease Isabella Ciccone, MPH

If approved, lecanemab-irmb would provide an at-home subcutaneous injection option for both treatment initiation and maintenance dosing for patients with early-stage Alzheimer disease.

FDA Clears Pilavapadin for Phase 3 Development in Diabetic Peripheral Neuropathic Pain Isabella Ciccone, MPH

The FDA raised no objections to Lexicon Pharmaceuticals’ pilavapadin for a phase 3 program, which will include 2-arm registrational studies, in patients with diabetic peripheral neuropathic pain.

Higher VMAT2 Target Occupancy Observed in Valbenazine Over Deutetrabenazine Extended-Release Capsules Louie Pasculli

Head-to-head PET imaging data indicated that valbenazine achieves significantly higher VMAT2 target occupancy than deutetrabenazine XR at therapeutic doses, with both treatments remaining well tolerated.

Managing Postpartum MS: Safety Data, Relapse Risk, and Real-World Practice Lindsay Ross, MD, Edith Graham, MD

Inside MS: A Clinician's Compass, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Edith Graham, MD. [LISTEN TIME: 40 minutes]

This Week on NeurologyLive® — January 26, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Todays Updates

Real-World Study Provides Support for Lamotrigine in Treating Non-Dystrophic Myotonias Louie Pasculli

Trial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.

NeuroVoices: Kathrin LaFaver, MD, FAAN, DipABLM, on What’s Ahead for Movement Disorder Care in 2026 Kathrin LaFaver, MD, FAAN, DipABLM, Isabella Ciccone, MPH

The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

Todays Updates

Real-World Study Provides Support for Lamotrigine in Treating Non-Dystrophic Myotonias Louie Pasculli

Trial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.

NeuroVoices: Kathrin LaFaver, MD, FAAN, DipABLM, on What’s Ahead for Movement Disorder Care in 2026 Kathrin LaFaver, MD, FAAN, DipABLM, Isabella Ciccone, MPH

The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

Latest News

A recent study linked maternal diabetes to a doubled risk of multiple sclerosis in offspring, highlighting prenatal factors in MS susceptibility.

If approved, lecanemab-irmb would provide an at-home subcutaneous injection option for both treatment initiation and maintenance dosing for patients with early-stage Alzheimer disease.

The FDA raised no objections to Lexicon Pharmaceuticals’ pilavapadin for a phase 3 program, which will include 2-arm registrational studies, in patients with diabetic peripheral neuropathic pain.

Head-to-head PET imaging data indicated that valbenazine achieves significantly higher VMAT2 target occupancy than deutetrabenazine XR at therapeutic doses, with both treatments remaining well tolerated.

Inside MS: A Clinician's Compass, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Edith Graham, MD. [LISTEN TIME: 40 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

News All Time

Levacetylleucine Meets Primary and Secondary End Points in Phase 3 Ataxia-Telangiectasia Study Isabella Ciccone, MPH

IntraBio reported that levacetylleucine showed symptom improvement in the phase 3 IB1001-303 study for ataxia-telangiectasia, and it intends to proceed with regulatory submissions in multiple regions.

NeuroVoices: Sneha Mantri, MD, MS, on Addressing Depression and Anxiety in Parkinson Care Marco Meglio

The chief medical officer at the Parkinson’s Foundation detailed how mood and behavioral symptoms shape quality of life in Parkinson disease and how clinicians can better identify and manage them.

FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy Isabella Ciccone, MPH

The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.

Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits Marco Meglio

Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.

Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome Louie Pasculli

A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.

Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time Marco Meglio

A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.

What the EC Decision on High-Dose Spinraza Means for SMA Care Marco Meglio, Stephanie Fradette, PhD

Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.

Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia Marco Meglio

Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.

This Week on NeurologyLive® — January 19, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: January 18, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC)!

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient Noah Stansfield

The therapy also received orphan drug designation from the FDA.

NeurologyLive® Friday 5 — January 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Amantadine Immediate Release Lowers Dyskinesia Risk in Early Parkinson Disease, Study Shows Louie Pasculli

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

Newborn Screening for Duchenne: Clinical and Policy Implications Marco Meglio

Paul Melmeyer, MPP, executive vice president, public policy and advocacy, Muscular Dystrophy Association, explains how adding Duchenne muscular dystrophy to the Recommended Unified Screening Panel reshapes early diagnosis, treatment timing, and family counseling.

Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival Marco Meglio

Published phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.

Exploring Depressive Symptoms in Low-IQ Youth with Refractory Epilepsy Janelle L Wagner, PhD, Shannon Brothers, PhD, Cortney Wolfe-Christensen, PhD, Louie Pasculli

A trio of clinician authors provided insights on a recently published paper assessing youths with refractory epilepsy and ways to combat depressive symptoms.

Recommended News For You

Smart exercise planning could boost recovery for people with cancer

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

Parkinson patient's gait is restored by a spinal cord stimulator.

Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria

New study links air pollution with higher rates of head and neck cancer

improvements in the treatment of prostate cancer resistant to chemotherapy.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals

Recommended Articles For You

Anemia Symptoms: What You Need to Know  

Unraveling the Genetic Mystery of Hereditary Spherocytosis 

Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers 

Angina Haemorrhagica Bullosa: What You Need to Know 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.

2.

Experts suggest Michelangelo depicted breast cancer in the Sistine Chapel fresco

3.

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients

4.

High numbers of rural patients cross state lines for cancer care

5.

Compared to previous estimates, a greater number of patients participate in cancer treatment trials.

1.

How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?

2.

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed

3.

Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment

4.

The Benefits and Risks of Transurethral Resection of Bladder Tumor 

5.

The Science Behind Imatinib: How It Targets Cancer Cells 

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

2.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

3.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot